Skip to main content
SpringerLink
Log in

Oncology Nurse’s Perspective

  • Chapter
Chemo Fog

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 678))

Abstract

Oncology nurses are increasingly recognizing the importance of chemotherapy-related cognitive impairment (CRCI) in the lives of their patients and are contributing to the state of the knowledge in this field of study. The Oncology Nursing Society has included treatment related changes in cognitive function as a priority in the 2009–2013 “Oncology Nursing Society Research Agenda and Priorities”. Related educational programming has been included at national nursing symposia. A brief review of some research conducted by oncology nurses is described.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahles TA, Saykin AJ. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 2001; 19:812–820.

    Article  CAS  PubMed  Google Scholar 

  2. Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized longitudinal trial. Cancer 2004; 100:2292–2299.

    Article  CAS  PubMed  Google Scholar 

  3. Tannock IF, Ahles TA, Ganz PA et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22:2233–2239.

    Article  PubMed  Google Scholar 

  4. Doorenbos AZ, Berger AM, Brohard-Holbert C et al. ONS Research Priorities Survey. Oncol Nurs Forum 2008; 35:E100–E107.

    Article  PubMed  Google Scholar 

  5. Oncology Nursing Society. Oncology Nursing Society 2009–2013 Research Agenda and Priorities. 2009. http://www.ons.org/research/information. Accessed 2009.

    Google Scholar 

  6. Ahles TA, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 2002; 3(Suppl 3):S84–S90.

    Article  CAS  PubMed  Google Scholar 

  7. Brown KA, Esper P, Kelleher LO et al. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. Pittsburgh: Oncology Nursing Society, 2001.

    Google Scholar 

  8. Klemp JR, Stanton AL, Kimler BF et al. Evaluating the effects of chemotherapy on cognitive function and quality of life in premenopausal women with breast cancer. Paper presented at: San Antonio Breast Cancer Symposium 2006; San Antonio.

    Google Scholar 

  9. Lezak MD, Howieson DB, Loring EW. Neuropsychological Assessment. 4th ed. New York: Oxford University Press; 2004.

    Google Scholar 

  10. Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology 2000; 14(1):75–79.

    CAS  PubMed  Google Scholar 

  11. Barnes DE, Cauley JA, Lui LY et al. Women who maintain optimal cognitive function into old age. J Am Geriatr Soc 2007; 55:259–264.

    Article  PubMed  Google Scholar 

  12. Grady D, Yaffe K, Kristof M et al. Effect of postmenopausal hormone therapy on cognitive function: the heart and estrogen/progestin replacement study. Am J Med 2002; 113(7):543–548.

    Article  CAS  PubMed  Google Scholar 

  13. Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women’s health initiative memory study. J Am Med Assoc 2004; 291(24):2947–2958.

    Article  CAS  Google Scholar 

  14. Yaffe K, Barnes DE, Lindquist K et al. Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging 2007; 28(2):171–178.

    Article  CAS  PubMed  Google Scholar 

  15. Cimprich B, Ronis DL. Attention and symptom distresss in women with and without breast cancer. Nurs Res 2001; 50(2):86–94.

    Article  CAS  PubMed  Google Scholar 

  16. Cimprich B, So H, Ronis DL et al. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-oncology 2005; 14:70–78.

    Article  PubMed  Google Scholar 

  17. Bender CM, Sereika SM, Berga SL et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-oncology 2006; 15:422–430.

    Article  PubMed  Google Scholar 

  18. Von Ah D, Harvison K, Carpenter J et al. Cognitive function in breast cancer survivors compared to healthy age-and education-matched women. Paper presented at: Oncology Nursing Society 10th Annual National Conference on Cancer Nursing Research 2009; Orlando FL.

    Google Scholar 

  19. Myers JS, Teel C. Oncology nurses’ awareness of cognitive impairment secondary to chemotherapy. Clin J Oncol Nurs 2008; 12:725–729.

    Article  PubMed  Google Scholar 

  20. Jansen CE, Miaskowski CA, Dodd MJ et al. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncol Nurs Forum 2007; 34:997–1005.

    Article  PubMed  Google Scholar 

  21. Thielen J. Women’s experiences of living with neurocognitive changes while undergoing chemotherapy for breast cancer. Paper presented at: ONS 10th National Conference on Cancer Nursing Research 2009; Orlando FL.

    Google Scholar 

  22. Von Ah D. Cognitive dysfunction and its relationship to quality of life in African American and caucasian breast cancer survivors. Paper presented at: ONS 10th Annual National Conference on Cancer Nursing Research 2009; Orlando FL.

    Google Scholar 

  23. Jansen C. Chemotherapy-related cognitive changes in breast cancer patients. Paper presented at: ONS 10th Annual Conference on Cancer Nursing 2009; Orlando FL.

    Google Scholar 

  24. Jansen CE, Miaskowski C, Dodd M et al. Chemotherapy-induced cognitive impairment in women with breast cancer: a critique of the literature. Oncol Nurs Forum 2005; 32:329–342.

    Article  PubMed  Google Scholar 

  25. Jansen C, Miaskowski C, Dodd M et al. Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncol Nurs Forum 2005; 32:1151–1163.

    Article  PubMed  Google Scholar 

  26. Myers JS. Proinflammatory cytokines and sickness behavior: Implications for symptoms of depression and cancer. Oncol Nurs Forum 2008; 35:802–807.

    Article  PubMed  Google Scholar 

  27. Myers JS. Chemotherapy-related cognitive impairment: Neuroimaging, neuropsychologic testing and the neuropsychologist. Clin J Oncol Nurs 2009; 13(4):413–21.

    Article  PubMed  Google Scholar 

  28. Myers JS, Pierce J, Pazdernik T. Neurotoxicology of chemotherapy as it relates to cytokine release, the blood brain barrier and cognitive impairment. Oncol Nurs Forum 2008; 35:916–920.

    Article  PubMed  Google Scholar 

  29. Lenz ER, Pugh LC, Milligan RA et al. The middle-range theory of unpleasant symptoms: an update. ANS Adv Nurs Sci 1997; 19(3):14–27.

    Article  Google Scholar 

  30. Lenz ER, Suppe F, Gift AG et al. Collaborative development of middle-range nursing theories: toward a theory of unpleasant symptoms. ANS Adv Nurs Sci 1995; 17(3):1–13.

    Article  CAS  PubMed  Google Scholar 

  31. Hess LM, Insel KC. Chemotherapy-related change in cognitive function: a conceptual model. Oncol Nurs Forum 2007; 24:981–994.

    Article  Google Scholar 

  32. Myers JS. A comparison of the theory of unpleasant symptoms and the conceptual model of chemotherapy-related changes in cognitive function. Oncol Nurs Forum 2009; 36:E1–E10.

    Article  PubMed  Google Scholar 

  33. Barton D, Loprinzi C. Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: The art of the possible. Clin Breast Cancer 2002; 3(Suppl 3):S121–S127.

    Article  PubMed  Google Scholar 

  34. Johnson M, Henke Yarbro C. Principles of oncology nursing. In: Holland JF, Frei E, eds. Cancer Medicine. 5th ed. Hamilton: Decker, Inc; 2000.

    Google Scholar 

  35. Oncology Nursing Society. Oncology services in the ambulatory setting (Position statement). 2006. http://www.ons.org/pubications/postions/RevAmbulatoryPractice.shtml. Accessed 2007.

    Google Scholar 

  36. Polovich M, Olsen M, Whitford J eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 3rd ed. Pittsburgh: Oncology Nursing Society, 2009.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Nursing, University of Kansas, 3901 Rainbow Blvd, Kansas City, Kansas, 66160, USA

    Jamie S. Myers

Authors
  1. Jamie S. Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA

    Robert B. Raffa PhD

  2. Department of Pharmacology, Temple University School of Medicine, Phhiladelphia, Pennsylvania, USA

    Ronald J. Tallarida PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Myers, J.S. (2010). Oncology Nurse’s Perspective. In: Raffa, R.B., Tallarida, R.J. (eds) Chemo Fog. Advances in Experimental Medicine and Biology, vol 678. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6306-2_3

Download citation

Publish with us

Policies and ethics

Search

Navigation